Compare Davita Inc (DVA) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Goldman Sachs Group Inc — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Goldman Sachs Group Inc trades at $1,144 (market cap $336.31B). The key difference: Goldman Sachs Group Inc is far larger — about 22.5× Davita Inc's market cap, and Goldman Sachs Group Inc pays a 1.58% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GS | |
|---|---|---|
Market Cap | $14.92B | $336.31B |
Sector | Health | Financials |
52-Week High | $235.71 | $1.14K |
52-Week Low | $103.87 | $700.41 |
Enterprise Value | $27.47B | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Goldman Sachs (GS) trades at $1,140, up 8.04% in the past 24 hours, with a bullish technical outlook and strong earnings momentum after beating EPS estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.89% net income margin and 15.69% ROE, supported by positive analyst sentiment and involvement in high-profile IPOs like Anthropic. Revenue growth accelerated to $58.28 billion in 2025, though cash flow trends remain volatile.
The outlook for GS is positive, driven by investment banking strength and AI-driven IPO opportunities, but risks include negative operating cash flows and elevated debt levels. Analysts maintain a consensus price target of $1,080, with 40% recommending Buy. Investors should weigh the company's profit growth against liquidity concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
